Cleveland Clinic has appointed Jaroslaw Maciejewski, MD, PhD, as chairman of the new Department of Translational Hematology and Oncology Research [1, 2].
This leadership appointment marks the establishment of a dedicated hub for molecular and biochemical research into blood and bone marrow cancers. By bridging the gap between laboratory discovery and clinical application, the department aims to accelerate the development of treatments for complex myeloid malignancies.
Dr. Maciejewski is a hematologist specializing in the diagnosis and treatment of bone marrow failure syndromes and myeloid malignancies [1, 2]. His professional focus includes conducting research on these specific diseases to improve patient outcomes. The new department is situated within the Cleveland Clinic's Taussig Cancer Institute and the Lerner Research Institute in Cleveland, Ohio [3, 4].
The primary objective of the new department is to lead focused research into the molecular mechanisms of blood cancers [2]. This strategic move allows the clinic to consolidate its efforts in translational medicine, a process where research findings are directly applied to patient care.
As chairman, Maciejewski will oversee the integration of biochemical research and oncology practice. His work involves identifying the drivers of bone marrow failure and developing targeted therapies for leukemia and other myeloid cancers [1, 3]. The appointment strengthens the institution's capacity to handle rare and aggressive blood disorders through a specialized research framework [2].
“Dr. Maciejewski will lead a new department focused on molecular and biochemical research into blood and bone marrow cancers.”
The creation of a specialized Department of Translational Hematology and Oncology Research indicates a shift toward a more integrated 'bench-to-bedside' model at Cleveland Clinic. By appointing a specialist in bone marrow failure and myeloid malignancies to lead the department, the institution is prioritizing the translation of complex biochemical data into actionable clinical treatments for some of the most difficult-to-treat blood cancers.
